| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1069 | 2020 |
| Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma M Keyaerts, C Xavier, J Heemskerk, N Devoogdt, H Everaert, C Ackaert, ... Journal of Nuclear Medicine 57 (1), 27-33, 2016 | 390 | 2016 |
| A standard set of value-based patient-centered outcomes for breast cancer: the International Consortium for Health Outcomes Measurement (ICHOM) initiative WL Ong, MG Schouwenburg, ACM Van Bommel, C Stowell, KH Allison, ... JAMA oncology 3 (5), 677-685, 2017 | 221 | 2017 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 180 | 2022 |
| Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer P Cottu, V D'Hondt, S Dureau, F Lerebours, I Desmoulins, PE Heudel, ... Annals of Oncology 29 (12), 2334-2340, 2018 | 138 | 2018 |
| Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre … F André, YH Park, SB Kim, T Takano, SA Im, G Borges, JP Lima, S Aksoy, ... The Lancet 401 (10390), 1773-1785, 2023 | 102 | 2023 |
| Somatic uniparental isodisomy explains multifocality of glomuvenous malformations M Amyere, V Aerts, P Brouillard, BAS McIntyre, FP Duhoux, M Wassef, ... The American Journal of Human Genetics 92 (2), 188-196, 2013 | 84 | 2013 |
| Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients M D’Huyvetter, J De Vos, V Caveliers, I Vaneycken, J Heemskerk, ... Journal of Nuclear Medicine 62 (8), 1097-1105, 2021 | 81 | 2021 |
| An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45 V Bjelic-Radisic, F Cardoso, D Cameron, E Brain, K Kuljanic, RA da Costa, ... Annals of Oncology 31 (2), 283-288, 2020 | 73 | 2020 |
| The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy M Berlière, F Roelants, C Watremez, MA Docquier, N Piette, S Lamerant, ... The Breast 37, 114-118, 2018 | 62 | 2018 |
| PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies FP Duhoux, G Ameye, CP Montano‐Almendras, K Bahloula, ... British journal of haematology 156 (1), 76-88, 2012 | 61 | 2012 |
| Colon cancer: update on adjuvant therapy MS Mano, F Duhoux Clinical colorectal cancer 7 (3), 178-183, 2008 | 51 | 2008 |
| Window of opportunity studies: do they fulfil our expectations? S Schmitz, F Duhoux, JP Machiels Cancer treatment reviews 43, 50-57, 2016 | 45 | 2016 |
| KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia S Medves, FP Duhoux, A Ferrant, F Toffalini, G Ameye, JM Libouton, ... Leukemia 24 (5), 1052-1055, 2010 | 43 | 2010 |
| Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data C van Marcke, A Collard, M Vikkula, FP Duhoux Critical reviews in oncology/hematology 132, 138-144, 2018 | 42 | 2018 |
| Tamoxifen and ovarian function M Berliere, FP Duhoux, F Dalenc, JF Baurain, L Dellevigne, C Galant, ... PLoS One 8 (6), e66616, 2013 | 36 | 2013 |
| The t (1; 9)(p34; q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias FP Duhoux, N Auger, S De Wilde, S Wittnebel, G Ameye, K Bahloula, ... Leukemia research 35 (7), e114-e117, 2011 | 33 | 2011 |
| Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine F Derouane, C van Marcke, M Berlière, A Gerday, L Fellah, I Leconte, ... Cancers 14 (16), 3876, 2022 | 29 | 2022 |
| Perioperative ketorolac in high risk breast cancer patients. Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial P Forget, M Berlière, A van Maanen, FP Duhoux, JP Machiels, PG Coulie, ... Medical hypotheses 81 (4), 707-712, 2013 | 29 | 2013 |
| A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor–positive breast cancer K Jhaveri, D Juric, YS Yap, S Cresta, RM Layman, FP Duhoux, C Terret, ... Clinical Cancer Research 27 (21), 5760-5770, 2021 | 28 | 2021 |
